IMA 'shocked' over Patanjali's claim on Coronil; demands explanation from Harsh Vardhan

Overweight, diabetic people at risk of developing nonalcoholic fatty liver disease

People who are overweight and have diabetes are at a higher risk of developing the non-alcoholic fatty liver disease as the prevalence of NAFLD is around 9 percent to 32 percent in the Indian population, the Union Health Ministry informed on Monday. Researchers have found NAFLD in 40 to 80 per cent of people who have type-2 diabetes, and in 30 to 90 per cent of people who are obese. Studies also suggest that people with NAFLD have a greater chance of developing cardiovascular disease, a statement said. Launching the operational guidelines for Integration of NAFLD, Union Health Minister Dr Harsh Vardhan said, The Health Minister noted that India is becoming the first country in the world to identify the need for action for NAFLD. Meanwhile, the Central government said that the Ayushman Bharat program has so far screened 838.39 lakh people for hypertension, 683.34 lakh for diabetes and 806.4 lakh for the three common forms of cancer through Health and Wellness Centres (HWC). They have so far organised 6.91 lakh yoga and wellness sessions at the community level.

Watch: Ramdev launches Covid-19 medicine Coronil, Harsh Vardhan attends event

Yoga Guru Ramdev launched Patanjali's ‘Coronil’ to cure Covid-19 on Friday. Patanjali Ayurved said Coronil has got Ayush Ministry’s certification as per WHO scheme. The company claimed that it is the first evidence-based medicine to fight Covid-19. Ramdev also released research paper to back Patanjali's solutions to Covid-19. The ayurvedic medicine against coronavirus was launched at an event in New Delhi. The event was presided by Union Ministers Harsh Vardhan and Nitin Gadkari. Patanjali had earlier introduced Ayurveda-based Coronil on June 23 last year. The Haridwar-based firm, however, had to face criticism as it lacked scientific evidence. The Ayush Ministry, back then, had indicated it as 'Immuno-booster' only. Coronil is developed by Baba Ramdev's Patanjali Research Institute. It had started work for an Ayurvedic remedy for Covid-19 in January, 2020.

Patanjali Coronil research papers released by Baba Ramdev | Oneindia News

Yoga Guru Baba Ramdev has released research papers on Patanjali's Coronil medicine, the anti-Covid Ayurvedic drug that he first launched in June 2020. Ramdev had then claimed it was a 'medicine' however it was approved as an 'immunity booster' by the Centre. #PatanjaliCoronil #Ramdev #Ayurveda

Pfizer vaccine is 94% effective in real-world study

The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing COVID-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies. Gloria Tso reports.

Covid-19 patients on dealing with Texas storm while in hospital

While most Texans had more than enough to worry about during the icy storm that led to power outages and water problem, some, like Tania Delacruz, had an added woe: Covid-19.

Flesh Eating disease: Australia reports rise in Buruli ulcer cases | Oneindia News

New cases of the Buruli ulcer, a flesh-eating disease have been detected in parts of Australia mainly in the areas of Melbourne. Alarm has been raised after multiple cases have been identified in Australia. According to the World Health organization, ‘at least 33 countries with tropical, subtropical and temperate climates have reported buruli ulcer in Africa, South America, and Western Pacific regions. #FleshEatingDisease #BuruliVirus #Pandemic

Top medical journal calls for three urgent steps against COVID-19

In an analysis, the Lancet COVID-19 Commission has called for three urgent actions in the COVID-19 response. "First, all regions with high rates of new COVID-19 cases, including the USA and the European Union (EU), should intensify measures to minimise community transmission and deploy COVID-19 vaccines rapidly," read the Lancet medical journal in its latest publication. Second, governments should urgently and fully fund WHO and the Access to COVID-19 Tools (ACT) Accelerator, including COVAX. Third, the G20 countries should empower the International Monetary Fund (IMF) and multilateral development banks to increase the scale of financing and debt relief. Success on all three priorities--containment of transmission, rapid vaccination, and emergency finance--will require improved global cooperation, it said. New lineages are increasing transmission of infection and raising risks in regions that have been less affected by COVID-19, including in sub-Saharan Africa. Additionally, acquired immunity from earlier COVID-19 infections might be less protective against reinfection with some of the new SARS-CoV-2 variants. Mutant lineages might also reduce the efficacy of COVID-19 vaccines and require adapted vaccines or boosters."* The medical journal also pointed out that at least half of the world's population lacks access to essential health services.

COVID-19: G7 leaders to boost vaccine commitment to poorer countries in COVAX programme

Both the EU and the US are expected to announce on Friday that they will double their funding to the World Health Organisation's COVAX programme to €1bn and €3.3bn respectively.